Company / Accounts Receivable
Amylyx Pharmaceuticals, Inc. Accounts Receivable History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$447.0K
FY2024
5-year range
$447.0K / $40.0M
FY2022-FY2024
Trend
-98.9%
vs FY2023
Sector context
#110 of 113
Health Care
What the data says
Among 113 Health Care companies, Amylyx Pharmaceuticals, Inc. is in the bottom 3% for accounts receivable. Declined from $15M to $447,000 over the past 2 years.
Based on SEC 10-K filings.
$447,000 in FY2024.
Declined from $15M to $447,000 over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 113This company $447.0K Sector average $1.1B
▼
-100.0% below sector average
Key checks
Key Insights
- In FY2024, accounts receivable decreased 98.9% year-over-year.
- Ranks #110 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $447.0K | -98.9% |
| FY2023 | $40.0M | +161.7% |
| FY2022 | $15.3M | - |
| FY2021 | - | - |
As of FY2024 · SEC 10-K · Updated Jul 2, 2026